Immunomedics, NeoRx news

NERX sued IMMU in 1991, charging that IMMU's imaging products using technetium-99, including ImmuRAID-CEA colorectal cancer imaging agent, infringed NERX's U.S. patent No. 4,877,868. Seattle-based NERX is seeking to permanently enjoin the manufacture and sale of the IMMU products in the U.S.

IMMU (Morris Plains, N.J.) contends that its imaging and therapy agents using direct labeling don't infringe NERX's patent. IMMU had filed for summary judgement, arguing that its activities were reasonably related to regulatory approval of its products and therefore fall under a special statutory exemption. ...